普洛药业
(000739)
| 流通市值：177.64亿 | | | 总市值：177.71亿 |
| 流通股本：11.58亿 | | | 总股本：11.58亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 7,763,882,133.27 | 5,444,486,087.31 | 2,730,189,121.97 | 12,021,863,029.21 |
| 营业收入 | 7,763,882,133.27 | 5,444,486,087.31 | 2,730,189,121.97 | 12,021,863,029.21 |
| 二、营业总成本 | 6,996,741,278.28 | 4,838,162,638.1 | 2,490,659,565.28 | 10,858,989,886.75 |
| 营业成本 | 5,821,188,101.99 | 4,043,570,318.77 | 2,074,526,168.27 | 9,155,202,967.93 |
| 税金及附加 | 43,578,080.32 | 27,536,402.53 | 11,560,775.82 | 56,309,811.43 |
| 销售费用 | 382,944,355.1 | 259,713,136.71 | 135,739,283.33 | 640,232,098.94 |
| 管理费用 | 312,968,154 | 204,260,092.13 | 107,741,561.05 | 480,940,845.39 |
| 研发费用 | 465,006,684.23 | 324,198,969.9 | 169,688,023.08 | 641,471,760.73 |
| 财务费用 | -28,944,097.36 | -21,116,281.94 | -8,596,246.27 | -115,167,597.67 |
| 其中:利息费用 | 16,593,234.64 | 10,350,464.49 | 4,679,152.24 | 28,581,876.49 |
| 其中:利息收入 | 51,303,110.61 | 26,348,057.71 | 12,730,989.19 | 92,174,157.39 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 15,003.9 | -42,550.68 | - | 7,965,391.23 |
| 加:投资收益 | 33,819,960.74 | 35,840,695.16 | 39,456,689.06 | -18,092,847.19 |
| 汇兑收益 | 0 | - | - | - |
| 资产处置收益 | 1,459,491.19 | 1,159,599.1 | 207,218.06 | 279,470.84 |
| 资产减值损失(新) | -39,227,687.24 | -28,683,809.33 | -17,834,633.53 | -70,224,534.92 |
| 信用减值损失(新) | 17,709,674 | 5,063,458.78 | 7,678,573.87 | 921,524.36 |
| 其他收益 | 61,738,518.58 | 40,588,542.69 | 29,399,795.97 | 128,348,756.48 |
| 四、营业利润 | 842,655,816.16 | 660,249,384.93 | 298,437,200.12 | 1,212,070,903.26 |
| 加:营业外收入 | 1,848,698.35 | 924,100.75 | 530,079.37 | 1,643,305.98 |
| 减:营业外支出 | 5,364,967.73 | 2,585,687.31 | 1,495,996.55 | 10,423,836.23 |
| 五、利润总额 | 839,139,546.78 | 658,587,798.37 | 297,471,282.94 | 1,203,290,373.01 |
| 减:所得税费用 | 138,950,536.87 | 95,516,386.28 | 48,895,021.36 | 172,443,650.71 |
| 六、净利润 | 700,189,009.91 | 563,071,412.09 | 248,576,261.58 | 1,030,846,722.3 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 700,189,009.91 | 563,071,412.09 | 248,576,261.58 | 1,030,846,722.3 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 700,266,086.74 | 563,047,273.19 | 248,547,145.11 | 1,031,121,698.55 |
| 少数股东损益 | -77,076.83 | 24,138.9 | 29,116.47 | -274,976.25 |
| 扣除非经常损益后的净利润 | 647,105,200.69 | 520,545,789.49 | 205,665,722.98 | 984,439,126.95 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.61 | 0.49 | 0.21 | 0.89 |
| (二)稀释每股收益 | 0.61 | 0.49 | 0.21 | 0.89 |
| 八、其他综合收益 | 937,413.11 | 318,525.63 | 91,753.66 | 10,713,506.8 |
| 归属于母公司股东的其他综合收益 | 937,413.11 | 318,525.63 | 91,753.66 | 10,713,506.8 |
| 九、综合收益总额 | 701,126,423.02 | 563,389,937.72 | 248,668,015.24 | 1,041,560,229.1 |
| 归属于母公司股东的综合收益总额 | 701,203,499.85 | 563,365,798.82 | 248,638,898.77 | 1,041,835,205.35 |
| 归属于少数股东的综合收益总额 | -77,076.83 | 24,138.9 | 29,116.47 | -274,976.25 |
| 公告日期 | 2025-10-22 | 2025-08-20 | 2025-04-18 | 2025-03-11 |
| 审计意见(境内) | | | | 标准无保留意见 |